Huiyu Pharmaceutical (688553.SH) two subsidiaries received multiple overseas drug listing licenses.
Huiyu Pharmaceutical (688553.SH) announcement, the company's subsidiary Seacross Pharma (E...
Huayu Pharmaceuticals (688553.SH) announced that its subsidiaries Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. have recently received marketing approvals for the company's products including injection sodium mebucainide, injection cetirizine, injection cyclophosphamide, and injection parecetamol sodium from the Drug Regulatory Authority of Turkmenistan, the Spanish Agency for Medicines and Medical Devices, the Italian Ministry of Health, and the UK Medicines and Healthcare Products Regulatory Agency respectively.
Related Articles
GigaDevice Semiconductor Inc. (03986) will fully exercise the oversubscribed rights issue, stabilize prices and end the stabilization period.
DYNAGREEN ENV(01330): "Green Dynamic Convertible Bond" will pay interest on February 25th.
LAUNCH TECH (02488): China Securities Regulatory Commission issues a filing notice for the company's H-share full circulation application.
GigaDevice Semiconductor Inc. (03986) will fully exercise the oversubscribed rights issue, stabilize prices and end the stabilization period.
DYNAGREEN ENV(01330): "Green Dynamic Convertible Bond" will pay interest on February 25th.
LAUNCH TECH (02488): China Securities Regulatory Commission issues a filing notice for the company's H-share full circulation application.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
